In this InvestorIntel interview, Tracy Weslosky talks to Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO, and Director Steve Saviuk about an update on the new drug Sabizabulin for the treatment of COVID-19 patients. Being accepted for review by Health Canada, Steve explains how Sabizabulin showed a 51.6% reduction in deaths in hospitalized adult patients with moderate to severe COVID-19.

Having recently reported their best quarter ever, Saviuk discusses Valeo’s record fourth quarter and fiscal year 2022 revenues which were up 274% and 105%, respectively. Steve goes on to provide an update on Valeo’s portfolio of high-growth potential respiratory/allergy, ophthalmology, and hospital specialty products that are driving revenues.

To access the full InvestorIntel interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory/Allergy, Ophthalmology, and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the necessary capabilities and a complete infrastructure to register and manage its growing product portfolio through all stages of commercialization.

To know more about Valeo Pharma Inc., click here

Disclaimer: Valeo Pharma Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].

In this InvestorIntel interview, Tracy Weslosky talks to Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO, and Director Steve Saviuk about Valeo’s record quarterly and annual revenues for the fourth quarter and the fiscal year 2022. Having reported their best quarter ever, Steve discusses how Valeo’s story can be summed up with, “growth and more growth.”

Over the course of the interview, Steve discusses the following highlights from Valeo’s record-breaking fourth-quarter and year-end 2022 financial results:

• Record quarterly revenues of $12.7 million in FQ4-22, up 274% over FQ4-21
• Record revenues in F2022 of $27.7 million, up 105% over F2021
• Record revenues forecasted in FQ1-23
• Creation of Ophthalmology Business Unit following the addition of XIIDRA^® and SIMBRINZA^®, expansion of Respiratory Business Unit to include allergy following the addition of ALLERJECT^®
• In excess of $60 million was raised in financings in 2022

With a sales force comprising 85 commercial representatives in the field, Steve goes on to provide an update on Valeo’s portfolio of high-growth potential products that focus on respiratory/allergy, ophthalmology, and hospital specialty products.

To access the full InvestorIntel interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory/Allergy, Ophthalmology, and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the necessary capabilities and a complete infrastructure to register and manage its growing product portfolio through all stages of commercialization.

To know more about Valeo Pharma Inc., click here

Disclaimer: Valeo Pharma Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].

What a difference a year makes. Last year at this time we were heading into wave something or other of COVID, lockdowns and travel restrictions were still in place and people everywhere were getting pretty sick and tired of the whole situation. In Canada, we had the added reminder of massive protests in Ottawa and various border crossings. Life in general was not straightforward, nor was it ideal for the average individual. One year later, that seems like a distant memory and life is pretty much back to normal as long as you don’t spend too much time following global politics.

You may be wondering why I’m doing this look back? Because almost exactly one year ago was the last time I had a look at today’s company.

Not only has the world changed considerably in the last 12 months, so has Valeo Pharma Inc. (TSX: VPH | OTCQB: VPHIF). Valeo Pharma is a fast growing pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory/Allergy, Ophthalmology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the necessary capabilities and a complete infrastructure to register and manage its growing product portfolio through all stages of commercialization.

On Monday, Valeo released it’s Fiscal 2022 results (for the year ended October 31, 2022) that included some pretty impressive growth in revenue and adjusted gross profit. But before we dig into the numbers here are a few key highlights from the last 12 months:

• In March 2022, the Company received final approval for the listing of its common shares and warrants on the Toronto Stock Exchange (“TSX”) with an effective trading date of March 29, 2022;
• In July 2022, the Company entered into a Commercialization and Supply Agreement with Novartis Pharmaceuticals Canada Inc. for the Canadian commercialization by Valeo of two innovative ophthalmic therapies, XIIDRA® and SIMBRINZA® in Canada;
• In July 2022, the Company entered into a License, Supply, and Commercialization agreement with Kaléo Inc. for the Canadian rights to ALLERJECT, (epinephrine injection, USP) auto-injector for the treatment of serious allergic reactions;
• In July 2022, the Company closed a non-dilutive US$30 million Secured Term Loan from Sagard Healthcare Partners;
• In August 2022, the Company appointed Kyle Steiger to the role of Senior Vice-President and Chief Commercial Officer and Jean-François Fournier as its new Business Unit Head – Ophthalmology;
• In September 2022, the Company entered into a Commercial Services Agreement with Veru Inc. for sabizabulin in Canada, a novel dual antiviral and anti-inflammatory agent being targeted for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death

Adding numerous commercial assets to Valeo’s product portfolio had a material impact on the top line as the Company posted record 2022 revenues of C$27.7 million for the year-ended October 31, 2022 compared to C$13.6 million for the year-ended October 31, 2021 for a 105% increase. Record adjusted gross profit was C$9.4 million for the year-ended October 31, 2022 compared to C$4.5 million for the year-ended October 31, 2021, representing a 109% increase. A lot of this growth came in the Company’s fiscal Q4 where record revenues were C$12.7 million for the quarter ended October 31, 2022 compared to C$3.4 million for the quarter ended October 31, 2021 representing a 274% increase. The investments Valeo has made during prior years in its corporate and commercial infrastructure is starting to pay off by providing considerable operating leverage which is fueling this growth and paving a path towards profitability.

Valeo now has a total of 14 treatments/therapies in its product portfolio which has the Company anticipating that all its business units will continue to produce strong revenue and margin growth in 2023 as it forecasts delivering record quarterly revenues again in the first quarter of 2023. Annualized revenue run-rate as at the end of FY-22 now exceeds C$50 million, which represents a significant increase over the FY-22 record revenues of C$27.9 million.

Over the last year, it appears Valeo Pharma has really hit its stride. As long as the Company can keep growing its top line without continuing to add to the 115 full-time employees, that revenue should start to filter down to the bottom line and make investors happy. With a market cap of C$50 million, Valeo is currently trading at 1x its annualized revenue run rate.

In this InvestorIntel interview, Tracy Weslosky interviews Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO and Director Steve Saviuk on their recent news release Valeo Pharma Raises Q4 and Full Year 2022 Revenue Guidance.

Steve starts by providing an update on how Valeo has increased its fiscal 2022 revenue guidance to CAD$27.5-28M. A forecasted increase exceeding 100% (compared to fiscal 2021 revenues of $13.6M), he discusses how the team and product line has made this a reality. Walking Tracy through an update on Valeo’s diversified portfolio of ‘life changing’ products as they relate to asthma therapies, Steve’s commentary on where the Company is heading makes this interview a must-see.

To access the full InvestorIntel interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.

About Valeo Pharma Inc.

Valeo Pharma is a fast growing pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respirology/Allergy, Ophthalmology and Specialty Products. Headquartered in Kirkland, Quebec, Valeo Pharma has the full capability and complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization.

To know more about Valeo Pharma Inc., click here

Disclaimer: Valeo Pharma Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].

Early in 2022 InvestorIntel updated readers about a company that was growing its revenue at an incredible rate of 128%. Fast forward to today and the same company continues to impress with a forecast FY 2022 revenue guidance “exceeding 100% compared to fiscal 2021.” That’s Tesla-like growth. Wow!

The company is Valeo Pharma Inc. (TSX: VPH | OTCQB: VPHIF) (“Valeo”).

So how is the company growing its revenue so fast you might ask?

Valeo’s specialty pharmaceuticals are selling very well, their business model allows Valeo to rapidly bring new pharmaceuticals to market, and their product range keeps growing

Valeo’s leading products in 2022 include asthma medicines Enerzair® and Atectura®, the low molecular weight heparin biosimilar REDESCA™, as well as the recently added ophthalmology products XIIDRA® SIMBRINZA®, and the ant-allergy product ALLERJECT®.

Valeo CEO Steve Saviuk stated: “Our lead products have delivered the strong growth we forecasted for 2022. With a first full year of commercial activities for Enerzair and Atectura now completed, both products are generating strong sequential quarterly increases in the number of total prescribers, total prescriptions and revenues…..The recent addition of our ophthalmic and severe allergy products in early August materially impacted our fourth quarter and we expect them to significantly contribute to our overall 2023 revenues as well”.

Valeo’s business model is also part of the reason for the rapid acceleration in revenues, as the company forms partnerships with pharmaceutical companies that do the research & development and manufacturing while Valeo concentrates on the regulatory requirements and the sales and marketing of the pharmaceutical products.

Valeo continues to grow its portfolio of products. In September 2022 Valeo announced a new product “sabizabulin”. Valeo entered into a Commercial Services Agreement with Veru Inc. for sabizabulin for the treatment of COVID-19 in Canada. Sabizabulin is a new dual antiviral and anti-inflammatory agent being targeted for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome and death. Anti-viral drugs are all the rage nowadays so this looks potentially like a winning move by Valeo. Valeo reported: “Treatment with sabizabulin 9 mg once daily, an oral, first-in-class, new chemical entity, microtubule disruptor that has dual anti-inflammatory and antiviral properties, resulted in a clinically meaningful and statistically significant 55.2% relative reduction in deaths compared to placebo. The results of the interim analysis of the Phase 3 COVID-19 study have been published in The New England Journal of Medicine (NEJM) Evidence.“

Note: Bold emphasis by the author.

Valeo’s product range of pharmaceuticals crosses several areas of medicine

Source: Valeo Pharma website

There is a lot to like about Valeo Pharma. The Company has been delivering on its targets and the management continues to successfully grow the business.

Valeo Pharma trades on a market cap of C$51 million. One to watch out for in 2023.

In this interview, InvestorIntel Publisher and Editor in Chief Stephen Lautens talks to Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO and Director Steve Saviuk about Valeoi’s record Q3 revenue and the addition of three new therapeutic drugs to its portfolio.

In the interview, which can also be viewed in full on the InvestorIntel YouTube channel (click here to access InvestorChannel.com), Steve discusses Valeo’s acquisition of two opthalmic therapies from Novartis Pharmaceuticals under a commericalization agreement, as well as a new license with Kaleo Inc. for an auto-injector for serious allergic reactions. These three additional Health Canada approved products, Steve says, “are accretive immediately to us. The three products had existing revenues of $27 million, and we expect that to grow so our total revenue base basically doubled on the day that we made that acquisition.”

Steve also discusses Valeo’s record Q3 revenues of $6.1 million from sales ($15.1 million YTD), and Valeo’s cash position of over $27 million. Steve says that “those are trends that we expect to see continue.” He also says that with the recent hiring of former Novartis VP Kyle Steiger as Senior VP of Valeo, and the expansion of its sales team to 80-85 people, Valeo is poised for rapid commercial and revenue growth.

To access the full InvestorIntel interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.

About Valeo Pharma

Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respirology/Allergy, Ophthalmology and Specialty Products. Headquartered in Kirkland, Quebec, Valeo Pharma has the full capability and complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization.

To know more about Valeo Pharma Inc., click here

Disclaimer: Valeo Pharma Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].